U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Duy Drugs Inc. - 542933 - 05/27/2020
  1. Warning Letters

CLOSEOUT LETTER

Duy Drugs Inc. MARCS-CMS 542933 —

Delivery Method:
Electronic Mail
Reference #:
20-HAFE4-WLCOL-12
Product:
Dietary Supplements
Drugs
Recipient:
Recipient Name
Mr. Ricardo Mayo-Alvarez
Recipient Title
President/Owner
Duy Drugs Inc.

1730 NW 79th Ave.
Doral, FL 33126
United States

doralphar@aol.com
Issuing Office:
Office of Human and Animal Food Operations Division IV East

United States

(787) 729-8500

Dear Mr. Mayo-Alvarez:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to Warning Letter 18-HAFE4-WL-05 dated August 28, 2018. It appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Kind regards,
/S/
Edwin Ramos
Director of Compliance Branch
OHAFO, Division IV East

Back to Top